GRI Bio (NASDAQ: GRI) Announces Board of Director Appointments Adding Leadership and Expertise Spanning a Combined 75 Years in Both Public and Private Sectors in the Life Sciences Industry

by barry-jtcir | Apr 24, 2023 | Press Releases

LA JOLLA, CA, April 24, 2023 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory,...

Vallon Pharmaceuticals Completes Merger with GRI Bio, Inc.

by barry-jtcir | Apr 21, 2023 | Press Releases

Combined company will operate as GRI Bio, Inc. and advance innovative pipeline of Natural Killer T (“NKT”) modulating therapies for the treatment of inflammatory, fibrotic and autoimmune diseasesInvestment proceeds expected to fund planned operations of...

Vallon Pharmaceuticals Announces Stockholder Approval of Merger with GRI Bio, Inc. and Reverse Stock Split

by barry-jtcir | Apr 20, 2023 | Press Releases

Vallon’s board approves 1-for-30 reverse stock split Merger expected to close April 21, 2023 PHILADELPHIA, PA, April 20, 2023 — Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) (“Vallon” or the “Company”) today announced that its...

Hello world!

by barry-jtcir | Apr 11, 2023 | Uncategorized

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Vallon Pharmaceuticals and GRI Bio Enter into Merger Agreement with Goal of Advancing Innovative Pipeline of NKT Cell Regulators

by barry-jtcir | Dec 13, 2022 | Press Releases

Combined company will operate as GRI Bio and advance innovative pipeline of Natural Killer T (NKT) regulating therapies for the treatment of inflammatory, fibrotic and autoimmune diseases GRI Bio has committed capital to fund planned operations of the combined company...